| 治疗良性前列腺增生药品使用情况的市场调查 |
| |
| 引用本文： | 吴楠,孙健,张秋桂,孙振球. 治疗良性前列腺增生药品使用情况的市场调查[J]. 北方药学, 2012, 9(9): 81-82 |
| |
| 作者姓名： | 吴楠 孙健 张秋桂 孙振球 |
| |
| 作者单位： | 深圳南山区疾病预防控制中心;万载县疾病预防控制中心;中南大学湘雅医学院 |
| |
| 摘 要： | 目的:了解中国良性前列腺增生(BPH)患者用药情况。方法:采用横断面调查的方法,对中国11个城市33个三级甲等医院门诊BPH患者用药情况进行调查。结果:5α-还原酶抑制剂非那雄胺在患者中采用百分比为最高(48.0%)。其次为-受体阻滞剂坦索罗辛(22.7%)。结论:研究结果可能会为临床BPH诊疗及治疗BPH药品的市场开发提供参考。
|
| 关 键 词： | 良性前列腺增生 药物 调查 |
Study on the drug market of benign prostatic hyperplasia in China |
| |
| Wu Nan,Sun Jian,Zhang Qiugui,Sun Zhenqiu. Study on the drug market of benign prostatic hyperplasia in China[J]. BEIFANG YAOXUE, 2012, 9(9): 81-82 |
| |
| Authors: | Wu Nan Sun Jian Zhang Qiugui Sun Zhenqiu |
| |
| Affiliation: | 3* (1.Shenzhen NanShan Centre for Disease Control and Prevention,Shenzhen 518054, China;2.WanZai Centre for Disease Control and Prevention,Wanzai 336100,China;3.Xiangya School of medicine,Central South University,Changsha,410078,China) |
| |
| Abstract: | Objective:To probe into the general information of drugs for benign prostatic hyperplasia. Methods: This cross -sectional study was performed in 33 medical centers located in 11 different cities in China. A survey investigated BPH patients who were asked to record their preferences in drugs. Results: 5-reductase inhibitor Finasteride was the most prescribed medication(48.0%),followed by -adrenoceptor antagonists Terazosin (22.7%). Conclusions: The study may also provides reference for the China BPH clinical practice and the BPH drug market. |
| |
| Keywords: | Benign prostatic hyperplasia Drug Investigation |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
